Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Elizabeth Smith

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Psychological Bulletin|August 24, 2011
Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individualsM Elizabeth Smith, Martha J Farah
Psychological Bulletin|August 24, 2011
Discussing smart pills versus endorsing smart pills: reply to Swanson, Wigal, and Volkow (2011) and Elliott and Elliott (2011)Martha J Farah, M Elizabeth Smith
Wiley Interdisciplinary Reviews. Cognitive Science|August 26, 2015
Cognitive enhancementMartha J Farah, M Elizabeth Smith, Irena Ilieva, et al.
Journal of Cognitive Neuroscience|May 15, 2008
Brain imaging and brain privacy: a realistic concern?Martha J Farah, M Elizabeth Smith, Cyrena Gawuga, et al.
Psychopharmacology|November 18, 2008
When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary studyMartha J Farah, Caroline Haimm, Geena Sankoorikal, et al.
AIDS (London, England)|August 30, 2008
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescentsJuan C Salazar, Pedro Cahn, Ram Yogev, et al.
The Journal of Allergy and Clinical Immunology|March 6, 2007
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenCourtney V Fletcher, Jaime G DeVille, Pearl M Samson, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2006
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)William T Shearer, Jaime G DeVille, Pearl M Samson, et al.
The Lancet. Infectious Diseases|February 4, 2011
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial, Abdel Babiker, Hannah Castro nee Green, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Psychological Bulletin|August 24, 2011
Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individualsM Elizabeth Smith, Martha J Farah
Psychological Bulletin|August 24, 2011
Discussing smart pills versus endorsing smart pills: reply to Swanson, Wigal, and Volkow (2011) and Elliott and Elliott (2011)Martha J Farah, M Elizabeth Smith
Wiley Interdisciplinary Reviews. Cognitive Science|August 26, 2015
Cognitive enhancementMartha J Farah, M Elizabeth Smith, Irena Ilieva, et al.
Journal of Cognitive Neuroscience|May 15, 2008
Brain imaging and brain privacy: a realistic concern?Martha J Farah, M Elizabeth Smith, Cyrena Gawuga, et al.
Psychopharmacology|November 18, 2008
When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary studyMartha J Farah, Caroline Haimm, Geena Sankoorikal, et al.
AIDS (London, England)|August 30, 2008
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescentsJuan C Salazar, Pedro Cahn, Ram Yogev, et al.
The Journal of Allergy and Clinical Immunology|March 6, 2007
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenCourtney V Fletcher, Jaime G DeVille, Pearl M Samson, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2006
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)William T Shearer, Jaime G DeVille, Pearl M Samson, et al.
The Lancet. Infectious Diseases|February 4, 2011
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial, Abdel Babiker, Hannah Castro nee Green, et al.
Pageof 1